Development of mucoadhesive solid lipid nanoparticles for enhanced oral bioavailability and antimalarial efficacy of artemether/lumefantrine
Tropical Journal of Pharmaceutical Research · 2026 · 25 (6) · 761-772
DOI: 10.4314/tjpr.v25i6.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tropical Journal of Pharmaceutical Research, 2026. Verfasst von Emmanuel Ossai und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To report the development of mucoadhesive solid lipid nanoparticles (SLNs) to enhance oral bioavailability and antimalarial efficacy of artemether and lumefantrine.
Methods
The SLNs were prepared via hot emulsion–ultrasonication using a lipid matrix composed of dika fat (Irvingia gabonensis) and Phospholipon® 90H. Chitosan coating was applied to confer mucoadhesive properties and prolong gastrointestinal residence time. Fourier transform infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC) were employed to determine the drug-excipient interaction and thermal properties of the nanoparticles, respectively. Antimalarial properties of the formulated nanoparticles were carried out in vivo using Plasmodium berghei-infected Wistar albino mice.
Results
The SLNs, formulated as individual and co-drug-loaded systems, achieved high encapsulation efficiencies (> 99 % for artemether; > 92 % for lumefantrine). Co-loading improved drug release compared to single-drug SLNs (artemether: 86.2 vs. 58.7 %; lumefantrine: 74.8 vs. 63.8 % over 6 – 8 h). The nanoparticles were spherical, with mean diameters 91.3 – 140.1 nm and polydispersity indices < 0.42. Fourier transform infrared spectroscopy and DSC analyses confirmed drug–excipient compatibility and stable incorporation of both drugs within the lipid matrix. In vivo evaluation in Plasmodium berghei-infected Wistar albino mice revealed a dose-dependent, statistically significant (p < 0.05) reduction in parasitemia for the SLN formulations compared to control.
Conclusion
Chitosan-coated SLNs offer a promising platform for oral delivery of artemether-lumefantrine, with potential to overcome current limitations in bioavailability and therapeutic consistency in malaria treatment.
Zitieren
APA
Ossai, E., Ugwuoke, P., Agbom, C., Ossai, E., Mumuni, M., Ezike, C., & Mbah, C. (2026). Development of mucoadhesive solid lipid nanoparticles for enhanced oral bioavailability and antimalarial efficacy of artemether/lumefantrine. Tropical Journal of Pharmaceutical Research, 25(6), 761-772. https://doi.org/10.4314/tjpr.v25i6.2
Vancouver
Ossai E, Ugwuoke P, Agbom C, Ossai E, Mumuni M, Ezike C, et al. Development of mucoadhesive solid lipid nanoparticles for enhanced oral bioavailability and antimalarial efficacy of artemether/lumefantrine. Tropical Journal of Pharmaceutical Research. 2026;25(6):761-772. doi:10.4314/tjpr.v25i6.2
BibTeX
@article{Ossai2026,
author = {Ossai, Emmanuel and Ugwuoke, Patience and Agbom, Chukwuemeka and Ossai, Edith and Mumuni, Momoh and Ezike, Christian and Mbah, Christian},
title = {Development of mucoadhesive solid lipid nanoparticles for enhanced oral bioavailability and antimalarial efficacy of artemether/lumefantrine},
journal = {Tropical Journal of Pharmaceutical Research},
year = {2026},
volume = {25},
number = {6},
pages = {761--772},
doi = {10.4314/tjpr.v25i6.2}
}
EUVIMED